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1.
Introduction The ability of platelets to multitask is critical to the arrest of bleeding after injury, and to the development of arterial thrombosis, which underlies stroke and coronary artery disease. Following the reflex vasoconstriction of an injured vessel, platelets are recruited to the wound site to which they adhere and aggregate to form a fragile plug in the initiation of haemostasis. Platelets then provide the requisite membrane for the assembly of the prothrombinase complex, thereby localising coagulation to the wound site. The local generation of thrombin catalyses the conversion of soluble fibrinogen to insoluble fibrin, which stabilises the plug into a firm clot that prevents bleeding and promotes healing. It is now apparent that different populations of platelets play different roles in the cascade of events in thrombus formation.
The concept of functionally different subpopulations of platelets or division of labour amongst platelets at wound sites is well reported. For example, Patel et al., 1 described differences between 'vanguard platelets', a subpopulation that is the first to adhere to collagen and a second population of 'follower platelets' that adhere over the top of these. Furthermore, it is now well accepted that even after strong activation, not all stimulated platelets become procoagulant. Accordingly, differential expression on the plasma membrane of phosphatidylserine (PS) or components of the prothrombinase complex have been reported after platelet activation with thrombin and/or collagen 2,3 (see Fig. 1 ). Indeed, an increasing number of studies show heterogeneity in platelet responses to agonists. Two distinct phenotypes are discernible in the literature, a procoagulant phenotype which externalises phosphatidylserine, binds tenase and prothrombinase complexes and accelerates coagulation at the wound site and an aggregating and contractile phenotype characterised by active integrin αIIbβ3 which pulls fibrin over the platelet plug to tighten the clot into an impermeable cell mass [4] [5] [6] [7] .
Over the last four decades, several subpopulations of platelets with different features have been identified, named and suggested as candidates for the procoagulant platelet. In this review we summarise these data, reveal attributes central to these platelet phenotypes and provide perspectives on the mechanisms and molecular targets in the procoagulant response of activated platelets. We suggest that the various phenotypes described actually form a spectrum of a single platelet phenotype, the procoagulant platelet. Finally, we examine the potential for targeting this platelet subpopulation as an antithrombotic approach. In this regard we discuss the potential of inhibitors of the water channel aquaporin-1 (AQP1) and the repurposing of carbonic anhydrase inhibitors as antiprocoagulant antithrombotics, which may selectively limit the platelet procoagulant responses while sparing platelet aggregation and secretion.
1.1
How one platelet becomes procoagulant whilst another does not A high and sustained calcium rise is required for PS externalisation, coagulation factor binding and calpain-mediated inactivation of αIIbβ3 integrin, and is a major difference between aggregatory and procoagulant platelets, possibly explaining their different derivations [8] [9] [10] [11] . It is well known that the procoagulant response of strongly activated platelets is preceded by calcium mobilisation from intracellular stores 10, 12, 13 ; this is associated with the activation of Ca 2+ activated chloride channels, resulting in an initial salt entry which is then followed by the influx of water 8 . The chloride ion entry causes membrane hyperpolarisation and enhances the electrochemical drive for Ca 2+ entry 14 through both store-operated and store-independent pathways; together these ensure a high and sustained level of cytosolic calcium required to drive the procoagulant response 8, 10, [12] [13] [14] . The pattern of calcium signalling is different in adherent aggregating platelets, which are rather characterised by intermittent spikes in calcium levels or oscillatory calcium responses and the sustained engagement of αIIbβ3 integrins 8, 10, 15, 16 . Furthermore, platelet age or level of oxidative stress may pre-commit platelets to aggregatory or procoagulant phenotypes as discussed later in this review.
2.1
Balloon shaped or ballooning phenotypes The earliest report of a ballooning platelet phenotype was in 1978 by Wester et al., who reported the ultrastructural changes platelets undergo to arrest bleeding after skin vessel transection 31, 32 . Changes in platelet morphology were investigated at high resolution by electron microscopy and a subset of platelets was observed to have assumed a ballooned shape, with fibrin deposited between platelet balloons. These ballooned platelets were an integral part of the platelet plug and stable clot 31, 32 . About two decades later, this phenotype was generated in vitro on a collagen matrix, and platelets shown to externalise PS after a sustained cytosolic calcium rise and in the presence of physiological levels of extracellular calcium 10 . Since then several studies have investigated the procoagulant attributes of this platelet phenotype and its contribution to arterial thrombus formation 8, 10, 17, 20, 21, 33, 34 . It is clear that ballooned platelets not only bind annexin-V as indication of PS exposure but provide an extended surface area for the assembly of the prothrombinase complex and contribute to the acceleration of coagulation at the wound site 8, 20, 21, 33, 34 . Ballooned phenotypes have been reported as either BP 8, 10, 34 , SCIP 17 , Fib-CAP 20,21 or BAPS 8 (Fig.1) , and show attributes similar to other candidates of the 'procoagulant platelet' such as the MPTP and COATED platelets 29, 35 .
2.2
Mitochondrial permeability transition pore (MPTP) phenotype In a recent study, Hua et al. showed that co-labelling of platelets with fluorescent conjugates of a tripeptide trivalent arsenical 4-[N-(S-glutathionylacetyl) amino] phenylarsonous acid (GSAO) and an α-granule marker identified a subpopulation of activated procoagulant platelets undergoing cyclophilin-D dependent necrosis 22 . GSAO likely covalently binds to proteins containing cysteine thiols 36 as it has been previously reported to covalently bind the molecular chaperone heat shock protein 90 (Hsp90) 37 . We have previously shown that the actin cytoskeleton undergoes remodelling and the cell membrane increases permeability during platelet transformation to the procoagulant phenotype 8 , and this would allow GSAO to label intracellular proteins in necrotic platelets 22 . Furthermore, GSAO platelets show striking similarities to the activated necrotic platelets described by Jobe et al., 24 as 'highly activated platelets', characterized by high-level PS externalization, high-level fibrinogen retention, antigenic modulation of αIIbβ3 and marked membrane vesiculation. Like GSAO platelets, the formation of this subpopulation of platelets was dependent on cyclophilin-D induced mitochondrial permeability transition pore (MPTP) formation and opening. Cyclophilin-D is considered a modulatory component of MPTP which may regulate pore opening to allow for cytosolic molecule influx, leading to increased matrix volume, disruption of mitochondrial outer membrane and oxidative stress 38, 39 . Accordingly, Cyclophilin-D inhibition (by Cyclosporin A, coenzyme Q, or bongkrekic acid) markedly reduced the formation of both MPTP and GSAO platelets in independent experiments 22, 24, 26 . Another platelet subpopulation exhibiting the MPTP phenotype is the COATED platelet. These were originally so named by Dale in 2005, as a subpopulation of platelets that were generated after 'CO'llagen 'A'nd 'T'hrombin stimulation 27 . Specific parameters characterize this PS exposing platelets, namely the surface expression of αgranule proteins such as FVa, strong binding of transglutaminase substrates, fibrinogen, von Willebrand factor, thrombospondin, fibronectin and α2-antiplasmin 27 .
2.3
Commonalities of candidate procoagulant platelets Like the ballooning phenotype of procoagulant platelets (BP, SCIP, BAPS, FIB-CAP), COATED platelets bind α-granule protein, fibrinogen 27, 28 , externalise PS 28 , promote microvesiculation 30 and become membrane permeable after activation 28 . Furthermore, convincing data also indicate COATED platelet formation is associated with rapid loss of loss of mitochondrial transmembrane potential (Δψm) 26 , a characteristic also described for MPTP and GSAO platelets 22, 24 . Other striking similarities in the formation and characteristics of the 'procoagulant platelet', as described in the literature, are shown in Fig. 1 . The overlap in features of these platelets is therefore strongly suggestive of a single procoagulant versatile subpopulation of platelets. We therefore propose that platelets previously described by any of these range of descriptors, that show the common characteristics indicated in the 'PROCOAG-ID' column of Fig. 1 , be simply referred to as procoagulant platelets.
The features of the procoagulant platelet have differed depending on whether it was investigated in suspension (COATED, MPTP, BNS, FIB-CAP or GSAO) or adherent to solid agonist-coated matrices (SCIP, MPTP, BNS, BAPS, FIB-CAP). Unlike in suspension, a solid matrix provides procoagulant platelets with an adhesion platform upon which unique morphological transformations can occur. Features such as procoagulant-spreading, observed in SCIP and BAPS platelets, have been identified after adhesion to agonist-coated surfaces 8, 17 , but not in suspension. The characteristics of the procoagulant platelet, identified under either adhesion or suspension conditions, are summarised in Table. 1. calcium, whether studied adherent to a collagen matrix or stimulated with collagen in suspension. A distinguishing feature, unique to adherent platelets, is the formation of procoagulant-spread structures. There are currently no identified features that suspended procoagulant platelets show that are unique to this mode of activation.
3.
Mechanisms of procoagulant platelet formation The seven candidates for the procoagulant platelet shown in Fig. 1 share a common mechanism of formation which we will now discuss; a further indication that these comprise a spectrum of a single platelet phenotype.
3.1
Agonist requirement for procoagulant platelet formation Collagen remains the most important single agonist for the formation of adherent procoagulant platelets in the presence of physiological concentrations of extracellular calcium; it accounts for 40-80% of the procoagulant platelets formed under this condition 8,10 (Fig. 1 ). In suspension however, co-stimulation with agonists of protease-activated receptors was often necessary to achieve a similar size of procoagulant subpopulation 22, 24 . With thrombin alone, the proportion of activated platelets that become procoagulant varied from 20-60% in suspended platelets to 1-30% in platelets adhered to inert surfaces ( Fig. 1 ).These differences are likely to be due to variations in experimental conditions and to the different agonist stimulation pathways; however, in both adherent and suspended platelets, signalling via the glycoprotein VI (GPVI) receptor is a major pathway for the formation of procoagulant platelets. Platelet activation with adenosine diphosphate, von Willebrand factor, or a thromboxane A2 mimetic alone does not or only weakly generates procoagulant platelets 18 . In addition, some studies report that platelet pre-treatment with aspirin has minimal effect on the generation of procoagulant platelets 22, 35 .
Adherent Platelets
Suspended Platelets
Calcium dependence of procoagulant platelets Platelet activation via GPVI or Gq-coupled protease-activated receptors leads to a sustained increase in cytosolic calcium owing both to extracellular calcium influx and calcium mobilisation from stores 12, 40 . The role of calcium signalling in the formation of procoagulant platelets is pivotal, as formation of these platelets is abrogated by the depletion of extracellular calcium or by BAPTA mediated chelation of cytosolic calcium 8,10 , (Fig. 1) ; notably, there needs to be a sustained rise in cytosolic calcium to activate downstream signalling for a procoagulant response 8, 10, 21, 22, 41 (Fig. 1 ).
3.3
The role of calpain Sustained elevated cytosolic calcium required for the procoagulant response will in tandem breach the threshold of [Ca 2+ ]Cyt required to activate the thiol protease, calpain 17, 42 . Major contractile cytoskeletal and membrane linker proteins such as actin, vinculin and myosin have been identified as calpain substrates 43 . Once activated, calpain may induce the proteolysis of these proteins, and aid the remodelling associated with the dramatic transformation of the procoagulant platelet. The fragmentation of the procoagulant platelet membrane and eventual release of PS-positive microvesicles is consistent with calpain action 44 . Indeed, we recorded a rise in levels of activated calpain during active membrane ballooning in collagen activated platelets (Fig. 2 ) consistent with previous reports of calpain activation in collagen-stimulated platelets 45, 46 . Extended focus images obtained at 20 min after platelet adherence to fibrillar collagen show the spatial location of exposed PS indicated in red (as monitored by membrane annexin-V accumulation), calpain indicated in cyan and reactive oxygen species (ROS) indicated in green. Calpain activity was monitored by the 7-Amino-4-chloromethylcoumarin (CMAC) based substrate, fluorogenic t-BOC-Leu-Met-CMAC substrate which yield fluorescent peptidase products with improved retention in live platelets. The generation of ROS during membrane ballooning was followed in realtime by means of MitoSox™ (ThermoFisher Scientific), which is rapidly oxidized by superoxide to produce highly fluorescent products. Chart shows the temporal profile of calpain activation, PS exposure and ROS generation in a ballooning human platelet. Written informed consent was obtained in accordance with the Declaration of Helsinki. Human blood was obtained from healthy, drug-free volunteers under the University of Bristol, United Kingdom, Research Ethics approval (E5736). Live cell imaging was performed at 25 °C using a spinning-disk confocal system as previously described 8, 18 . Scale bar represents 3 µm. Data are representative of 4 independent experiments.
3.4
Integrin activation The structure and function of the platelet integrin αIIbβ3 is extensively reviewed elsewhere 47, 48 . This integrin is the best characterised of the platelet integrins, yet reports of its role in the formation of procoagulant platelets are conflicting 8, 21, 25 . For example after collagen stimulation, the BAPS phenotype of platelets showed high fibrinogen binding and αIIbβ3 activation, however BP, COATED, SCIP, MPTP and FIB-CAP platelets vary in this respect 9 (Fig. 1) . Some of the discrepancies may result from differences in kinetics of integrin activation. Platelets stimulated with convulxin/thrombin showed high fibrin and fibrinogen binding, which was associated with decreased PAC-1 binding after an initial peak 11 ; this supports previous reports of secondary inactivation of integrin αIIbβ3 9,17 and a conclusion that its activity during the formation of procoagulant platelets is transient. Moreover, it is possible that fibrinogen and fibrin bind to distinct sites on integrin αIIbβ3 15, [49] [50] [51] , and binding to each may be modulated differently by the mechanisms of integrin inactivation.
3.5
Chloride ion (Cl -) entry and a role for TMEM16F Our pooled data indicate an association between the platelet procoagulant response and Clentry ( Fig. 1) ; strong stimulation of platelets with collagen and or thrombin induce Clentry, which drives membrane hyperpolarisation and PS exposure 14 . There is also good evidence that TMEM16F or Ano6 is a key channel for Clentry in this response 52, 53 . Indeed, ablation of TMEM16F 54 or the blockade of calcium-activated Clchannels with small molecule inhibitors markedly diminished the platelet procoagulant response 8 . Accordingly, membrane ballooning was ablated in the Scott patient's platelets, thus indicating an important role for TMEM16F in the platelet procoagulant response 8, 9, [53] [54] [55] [56] [57] .
3.6
The procoagulant platelet is under oxidative stress Independent of granular release, the oxidizing agent H2O2 alone can induce a cyclophilin-D dependent loss of mitochondrial transmembrane potential (Δψm) due to MPTP formation and opening 24 ; this effect is calcium-independent and is mediated by thiol oxidation 58, 59 . The pooled evidence (Fig. 1) indicates that thrombin alone is a weak agonist for inducing the procoagulant response in activated platelets; however once under oxidative stress, platelets are 6 times more likely to become procoagulant with thrombin stimulation alone 24 . This suggests a role for intracellular oxidative stress and reveals an ancillary pathway independent of strong stimulation for the formation of the 'procoagulant platelet'. Interestingly, oxidative stress alone has been shown to have no effect on fibrinogen binding, PS externalization, or granule release, raising the possibility that intravascular oxidative stress may play a role only in the priming of platelets for procoagulant response. This fits the observation that platelet aging, which has been reported to be associated with glutathione peroxidase-1 or NADPH oxidase dysfunction and oxidative stress 60,61 may also prime and commit platelets to the procoagulant pathway. Equally, drugs or oxidizing agents that potentiated platelet oxidative stress or MPTP formation/opening have been shown to promote the formation of procoagulant platelets 24, 26 . Consistent with these and related findings previously reviewed 60 , we observed that the procoagulant response of human platelets adhering to collagen was associated with increased superoxide generation (Fig. 2) .
3.7
A phenotype that gains function by dying Although it is clear that procoagulant platelets are undergoing a death process, the literature is ambivalent on whether this is by apoptosis 26, 62 or necrosis 8, 22 , indicating that the process may be strictly neither. Instead, it follows a pathway analogous to necrosis, but differentiated by a gain of procoagulant function. This pathway is induced by external ligand and characterised by the following features: (1) calcium dependence 8, 10, 12, 18 (2) cyclophilin-D and but not Bax/Bak ablation dependence 22, 24 (3) formation/opening of mitochondrial permeability transition pore 24, 58 , (4) early and rapid loss of Δψm 24 , (5) intracellular oxidative stress 8,22,26 , (6) membrane ballooning due to a tightly regulated fluid entry system 8,10 , (7) an early increase in membrane permeability associated with microtubule unwinding and (8) calpain mediated remodelling of the actin-cytoskeleton 44, 63 . Characteristically, these events are caspase-independent ( Fig. 1 ), yet they drive the amplification of thrombin generation through the combined increase in membrane PS exposure and membrane surface area and microvesiculation 8, 18, 24 . It is interesting to note, that while cell death is classically associated with a loss of function, for the procoagulant platelet the death process is clearly mechanistically important.
3.8
The procoagulant response is regulated by fluid entry A key event during procoagulant platelet formation is the irreversible membrane swelling or ballooning which results from the physical disruption of the membrane-cytoskeleton interaction, and an increase in internal hydrostatic pressure provided by a coordinated fluid entry system 8 . Balloon formation is reported in adherent platelets 8, 18 as well as in stimulated platelet suspensions 9, 64 ; here in Fig. 3 , we illustrate its formation mechanism. The fluid entry requirement for ballooning distinguishes this process from blebbing, which is the formation of retractable membrane protrusions. Blebbing is often used interchangeably with 'ballooning' 10, 65 ; whereas both events illustrated in Fig. 3 are distinct and driven by separate mechanisms 8 . For example, (i) balloons, but not transient membrane blebs, are procoagulant; (ii) ballooning but not bleb formation requires disruption to the platelet microtubule cytoskeleton and increased membrane permeability; (iii) unlike blebs, procoagulant ballooning is irreversible and consequent upon Na + , Cland water entry, and (iv) whereas the hydrostatic pressure required for bleb formation is fluid entry-independent, the rapid membrane expansion associated with ballooning requires fluid entry driven by the osmotic pressure of salt entry 8 (Fig. 3) . Precision is therefore required when discussing these events in platelets. (A) which weakens the membrane-cytoskeleton interaction and allows internal hydrostatic pressure to drive membrane protrusions (< 1µm diameter). This may be accompanied by a further detachment of the membrane from the cortex and a total volume change of < 10% (B). The recruitment of myosin to the expanded cortex enables bleb retraction (C, D) 66, 67 . Blebs were shown to form at one or more sites on platelet membranes upon contact with collagen, and are retractable and may be re-formed 8 . At some point, usually a single bleb would undergo a rapid increase in volume resulting in a characteristic platelet balloon (E) 8 .
4.0: Clinical relevance and translational potential for procoagulant platelets
Globally, cardiovascular disorders (CVD) remain the largest single contributor to mortality and morbidity 68, 69 . The role of the procoagulant platelet in platelet-driven thrombosis may underlie this statistic. For example, on the one hand low levels of procoagulant platelets have been shown to correlate with increased frequency of acute ischemic stroke complications, especially after thrombolytic therapy and increased spontaneous intracranial haemorrhage [70] [71] [72] ; and on the other, high levels of these platelets correlate with transient ischemic attack and stroke 73, 74 and with milder haemorrhagic phenotype in severe hemophilia 75 . It may therefore be possible to exploit procoagulant platelets either through targeting them pharmacologically or through identifying them as biomarkers, in the management of thrombotic cardiovascular disease.
Procoagulant platelets as clinical biomarkers
There is a need for universally accepted markers and/or identity criteria for the clinical assessment of thrombotic or bleeding tendency. It is possible that clinical markers could be designed based on the shared attributes of procoagulant platelets, and their identity criteria could be based on their commonalities shown in Fig. 1 . For example, evaluation of blood from healthy donors for procoagulant platelets, based on the combined expression of activated coagulation proteins and PS externalisation, showed that about 31.67 ± 13.2% (mean± SD), of platelets can assume this phenotype after dual stimulation with collagen and thrombin as previously reported 27, 73 . This figure varied widely between donors but appeared conserved within donors over time 29 , a clinical feature that may be exploited to individualise and monitor bleeding or thrombotic tendency in anticoagulation therapy or surgical units. Furthermore, classical features of the procoagulant platelet, such as increased membrane permeability 8 , will enable their in vitro identification by quick tests utilising low molecular weight cell impermeant dyes such as propidium iodide which label DNA and RNA 76 . Also, the report of GSAO earlier described as a marker of procoagulant platelets demonstrates the feasibility of this approach 22 . Other features such as a strong fibrinogen or coagulation factors (FVa, FXa) binding (Fig. 1) , can also be used to identify and quantify the preponderance of procoagulant platelets in clinical settings, using image based or flow cytometric analysis 3 . Such assessment, when done before major surgical intervention, may provide reliable data to enable the prediction of whether a patient has a tendency to bleed or will be at risk of thrombosis. In addition, these data provide a lead for the development of new bedside medical devices, for measuring platelet function and with predictive capabilities for bleeding disorders. For example, the in vitro formation of BP, BAPS, FIB-CAP, GSAO or COATED platelets was a strong correlate of in vivo arterial thrombus formation (Fig. 1 ).
4.2
Molecular drivers of procoagulant membrane dynamics as new antithrombotic targets Newer data provide insight into the molecular mediators and drivers of the platelet procoagulant response 8, 18, 34 . These molecular mechanisms reveal alternative targets for the regulation of thrombosis, which may spare essential secretion and other platelet functions 77, 78 . Since we had recently shown that blockade of P2Y1 and P2Y12 does not inhibit platelet procoagulant balloon formation or microvesiculation 18 , there is an opportunity for development of a new class of antithrombotics that target platelet procoagulation. For example, carbonic anhydrases 1, 2 and 13 have been recently identified as new potential anti-thrombotic targets 78, 79 , for which there are already inhibitors in clinical use such as the mild diuretic acetazolamide. We have recently shown that acetazolamide is a potent antithrombotic in vivo ( Fig. 4 and 8,78,79 ) , and has the potential to be a genuinely novel approach to the management of thrombotic disease. The signalling pathway involved in the antithrombotic actions of acetazolamide might include the regulation of reactive oxygen species by carbonic anhydrase enzymes, but at the moment there is no evidence in the literature. However, several reports indicate that carbonic anhydrase inhibitors are also capable of blocking water entry via the water channel AQP1 [80] [81] [82] [83] , and this may also be an important mechanism of action. Consistent with this, we have recently show AQP1 to potently regulate thrombus formation in vivo 77 , implicating it as a target for development of novel antithrombotic drugs 84, 85 . A major clinical side effect associated with current antithrombotic regimens in the management of CVD is the significant bleeding resulting from the use of dual anti-platelet therapy, for example, aspirin and P2Y12 blockers usually targeting the inhibition of platelet secretion. This status quo therefore demonstrates a need for alternative targets for the control of thrombotic events associated with CVD. With the procoagulant response of activated platelets critically reliant on morphological transformations, molecular mediators critical to the fluid entry mechanism which drive this event provide new approaches or target genes for the control of bleeding and thrombotic disorders. Furthermore, this may reveal new molecular mechanisms in diseases associated with disorders of haemostasis. It is well established that platelets secrete a plethora of releasates essential for the maintenance of vascular integrity and cardiovascular haemostasis 86 .
Consequently, a new antithrombotic approach that spares essential platelet secretion will potentially limit or eliminate the well-known side effects of antiplatelet therapies.
It is rather surprising that 25% or more of patients on antiplatelet drugs go on to suffer an ischaemic event 87 . Controlled trials of aspirin for the long-term secondary prevention of ischaemic events reports only a 13% relative reduction in risk of recurrent stroke 88, 89 . Similar low percent reductions were reported in studies evaluating the effects of aspirin in the 4-week risk period of recurrent stroke or intracerebral haemorrhage after short-term treatment for stroke. Together, these indicate that the present 'secretion-driven' approach to controlling platelet function in thrombosis is not optimal. Also, newer data show that platelets pre-treated with aspirin or from patients administered aspirin still showed full procoagulant response upon stimulation 22, 90 (Fig. 1) . The heterogeneity of activated platelets comes with unique challenges for drug therapy; aspirin for instance, will likely affect only aggregating platelets, which may present as conventional spread, non-ballooning platelets (CSNB) on collagen matrix 8 . Therefore, co-administration of agents like acetazolamide that suppress platelet procoagulant responses and thrombus formation by distinct mechanisms, may prove effective to limit the procoagulant response of platelets in patients already on aspirin. The existing literature suggests a need for such clinically effective antiplateletantiprocoagulant regimen 87 .
4.3
Potential Challenges of Procoagulant Platelet Inhibition Platelet procoagulant activity has been linked to stroke and coronary artery disease 71, 91, 92 , however this activity is also vital for haemostasis after vessel injury 71 ; thus its blockade as an antithrombotic approach may precipitate a bleeding diathesis if not fine-tuned. For example, the bleeding defect of Scott patients may be attributable to an aberrant procoagulant activity 8, 93, 94 . Also, prolonged bleeding times have been reported in TMEM16F null mice which showed a deficiency in Ca 2+dependent PS exposure and procoagulant activity in platelets 53, 55 . Fine tuning of therapy may therefore be required. Targeting platelet aquaporins however may achieve this fine tuning, since we have recently shown that mice lacking AQP1 show normal haemostasis whereas thrombus formation was significantly attenuated 77 . In addition, it may be possible to envisage the use of lower dose acetazolamide in combination with lower dose aspirin, thereby achieving antithrombotic activity at doses lower than currently recognised to cause their clinical adverse effects.
Conclusion
The major platelet phenotypes identified over the last 40 years, to support coagulation are essentially a versatile subpopulation of activated platelets, which we now suggest be referred to as procoagulant platelets. Procoagulant platelets undergo morphological transformations which amplify the surface area required for phosphatidylserine exposure and the acceleration of coagulation. Molecular drivers of procoagulant membrane dynamics provide distinct targets for the regulation of procoagulant platelets' role in thrombosis. Targeting the water channel AQP1 or carbonic anhydrase enzymes may therefore represent novel approaches in the management of thrombotic disease, both arterial and venous, with potential to suppress the function of procoagulant platelets and selectively limit thrombosis with minimal effect on other platelet functions.
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